With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.

In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry, academic KOL, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations.

Join Mironid, AstraZeneca, Novartis, Maza Therapeutics, Harvard Medical School, and more as you dive into critical topics investigating IgAN, FSGS, PKD, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need.

View the full event program here: https://ter.li/ncjxqh